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Abstract Adoption of Quality by Design (QbD) principles,
regulatory support of QbD, process analytical technology
(PAT), and continuous manufacturing are major factors
effecting new approaches to pharmaceutical manufacturing
and bioprocessing. In this review, we highlight new technol-
ogy developments, data analysis models, and applications of
Raman spectroscopy, which have expanded the scope of
Raman spectroscopy as a process analytical technology.
Emerging technologies such as transmission and enhanced
reflection Raman, and new approaches to using available tech-
nologies, expand the scope of Raman spectroscopy in phar-
maceutical manufacturing, and now Raman spectroscopy is
successfully integrated into real-time release testing, continu-
ous manufacturing, and statistical process control. Since the
last major review of Raman as a pharmaceutical PAT in 2010,
many new Raman applications in bioprocessing have
emerged. Exciting reports of in situ Raman spectroscopy in
bioprocesses complement a growing scientific field of biolog-
ical and biomedical Raman spectroscopy. Raman spectrosco-
py has made a positive impact as a process analytical and
control tool for pharmaceutical manufacturing and
bioprocessing, with demonstrated scientific and financial ben-
efits throughout a product’s lifecycle.
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Introduction
Raman spectroscopy is an optical spectroscopy technique that
provides a Bmolecular fingerprint^ of a sample. As an optical
method, Raman enables nondestructive analysis of chemical
composition and molecular structure. Applications of Raman
spectroscopy in polymer, pharmaceutical, bioprocessing, and
biomedical analysis have surged in the past three decades as
laser sampling and detector technology has improved.
Because of these technological advances, Raman spectrosco-
py is a practical analysis technique inside and outside the
laboratory. Raman spectroscopy is an established process an-
alytical technology (PAT) tool. Since the 1980s, Raman spec-
troscopy has been used to study active pharmaceutical ingre-
dients (API). Raman spectroscopy as a tool for API analysis
has been described for many applications, including poly-
morph identification, quantitative analysis, in situ crystalliza-
tion monitoring, real-time release testing, pharmaceutical unit
operations, and process-induced transformations [1–5]. In ad-
dition to identifying isolated polymorphic forms, mixtures of
forms can be analyzed and quantified [6, 7]. The diverse struc-
tures that have been measured by Raman, from the discovery
laboratory to the manufacturing environment, show that
Raman can reliably provide quantitative data. In-line Raman
spectroscopy can control critical process parameters, enables
real-time process corrections, and ensures consistent produc-
tion of the correct API form. We highlight new applications in
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API synthesis and crystallization, real-time release testing,
flow or continuous manufacturing, and new developments in
Raman spectroscopy for understanding and controlling
bioprocesses.
Regulatory perspectives and guidance
A philosophical shift in pharmaceutical manufacturing
quality, which is strongly encouraged by regulatory agen-
cies, has created opportunities to integrate real-time pro-
cess analytics into manufacturing processes. In 2002, the
U.S. Food and Drug Administration (FDA) launched an
initiative to encourage innovation in manufacturing tech-
nology and quality system approaches. The FDA 2004
PAT framework strongly emphasized a shift from tested-
in quality after the drug product was produced to building
in quality throughout production with Bcontinuous real
time quality assurance^ [8]. The European Medicines
Agency (EMA) established a PAT team in 2003, which
released guidance documents on process PAT, quality by
design (QbD), and real-time release testing. International
Conference on Harmonization (ICH) Q8, Q9, Q10, and
Q11 documents reinforced FDA and EMA guidance,
which has been implemented in the USA, European
Union, and Japan since 2009. Importantly, the FDA and
ICH documents provided a strategic guidance, rather than
prescriptive guidance, on developing an approach to un-
derstand and manage risks that might affect critical qual-
ity attributes. PAT has an important role in this new
framework to understand and manage risk throughout a
pharmaceutical product’s lifecycle. Recently, these princi-
ples were extended to bioprocessing. As a PAT in phar-
maceutical manufacturing and bioprocessing, Raman
spectroscopy has demonstrated value from scientific un-
derstanding to process control.
Instrumentation and data analysis techniques
Over the past 25 years, Raman spectroscopy instrumentation
has evolved from home-built academic laboratory instruments
to robust commercially available solutions-based systems.
The advent of stable laser sources, high-speed optical fibers,
volume holographic gratings, and low-noise charge coupled
device detectors enabled robust commercial Raman spectros-
copy instrumentation. Newer commercial instruments are
straightforward to use because they do not require constant
realignment or sophisticated knowledge of optics, are
equipped with instrument control software, and are integrated
with Raman spectral libraries. Thus, Raman spectroscopy is
accessible to scientists and environments beyond the academ-
ic research environment.
Modern instrumentation has been reviewed in detail else-
where [9–11]. Briefly, there are three basic components of a
Raman spectrograph, including a laser, sampling optics, and
detector. We will focus on laser wavelength and fiber optic
sampling probes in terms of their impact on Raman spectros-
copy as a PAT. Inelastic scattering is a weak phenomenon,
occurring only in a small amount of photons. Modern
Raman instrumentation optimizes the amount of inelastically
scattered photons and their detection. Modern Raman instru-
ments use a laser as the illumination source because it is a
high-intensity monochromatic source of light. While the laser
wavelength can vary from the UV to the near-infrared (λ =
200–1064 nm), most pharmaceutical or bioprocessing appli-
cations use near-infrared wavelengths (λ = 785 or 830 nm),
primarily to minimize fluorescence interferences. For exam-
ple, in Chinese hamster ovary (CHO) cell culture
bioprocesses, autofluorescence from intracellular NADH and
flavins occur in visible wavelengths and the strong autofluo-
rescence necessitates Raman measurements in the near-
infrared wavelengths (λ = 785 nm or 830 nm) even though
the scattering efficiency is lower in the near-infrared compared
with UVand visible wavelengths [12, 13].
Although near-infrared wavelengths are used primarily to
minimize interference from fluorescence, there are other ben-
efits that are not as widely recognized. All light-cell (or parti-
cle) interactions are important considerations in choosing a
wavelength and sampling optics for pharmaceutical
manufacturing and bioprocessing applications. Raman scatter-
ing occurs in the presence of fluorescence, optical scattering,
and optical absorbance. Optical scattering and absorption ef-
fects are becoming increasingly important to understand, es-
pecially as Raman spectroscopy moves toward in situ mea-
surements in turbid media. Most cell and tissue spectroscopy
is performed in the Btherapeutic^ near-infrared window (650–
1350 nm) because optical scattering is dominant and water
absorption is at a minimum [14, 15]. The same principle ap-
plies to pharmaceutical or bioprocess measurements, where it
is desirable to minimize optical absorption. Optical absorption
can arise from water, media chromophores, or a pigmented
cell. Optical scattering arises from refractive index mis-
matches. Particles, bubbles, or droplets with sizes approaching
the excitation wavelength exhibit Lorenz-Mie scattering,
which causes aqueous systems to become turbid. Photons
can be scattered multiple times, resulting in photons being
diffusely distributed in a turbid media. API or excipient parti-
cles and cellular organelles, such as mitochondria and nuclei,
also strongly scatter light [16, 17]. Understanding photon
transport in turbid media is an important consideration for
quantitative Raman spectroscopy applications in content uni-
formity, real-time release testing, and in situ bioprocess
control.
Sampling optics may be a microscope for high spatial res-
olution measurements, wide area or transmission for bulk
638 K.A. Esmonde-White et al.
measurements, or an immersion optical fiber probe for in-
process measurements. Fiber optic probes can be interchanged
on an instrument, thus extending the capabilities of a Raman
instrument. For example, a single Raman instrument can be
equipped with a microscope, a probe optimized for solids
identification, and a probe optimized for in situ reaction mon-
itoring. This sampling versatility is an attractive feature as a
PAT, especially in-process development and technology trans-
fer. As an optical spectroscopy technique, Raman spectrosco-
py can be performed outside of the laboratory using fiber optic
instrumentation. An important question when selecting a
fiber-optic probe for measurements in turbid media or solids
is the desired sampling volume where optical scattering is
significant.
Much research has been devoted in developing Raman
spectroscopy for pharmaceutical solids analysis, taking
into consideration process compatibility, validation, and
ease of use. Figure 1 shows the variants of Raman spec-
troscopy that utilize fiber optic probes. Traditional ap-
proaches employed fiber configurations with minimal sep-
aration between the excitation and collection fibers
(Fig. 1a). This technique is called backscattered Raman,
and the signal collected is mainly from superficial layers
with minimal or no signal recovery from subsurface
layers. Raman microscopy uses an epi-illumination con-
figuration, with the microscope objective both delivering
focused laser light to the sample and collecting Raman-
scattered photons. Wide area Raman, also called large
volumetric or global illumination Raman, (Fig. 1b) uti-
lizes a defocused laser beam to illuminate a large area
within the sample. The collection and illumination areas
are completely overlapping, and this approach has been
shown to be an effective means of sampling superficial
and deep layers, and improves upon non-representative
(or sub-sampling) issues encountered using backscattered
Raman [18, 19]. Extension of diffuse reflectance princi-
ples and fiber-probe designs to Raman spectroscopy is
called spatially-offset Raman spectroscopy (SORS).
SORS employs a larger (1–3 mm) separation between
the illumination and collection fibers (Fig. 1c). The fiber
separation enables collection of subsurface signal, even
through millimeters or centimeters of turbid media, be-
cause Raman-scattered photons from subsurfaces are dif-
fusely scattered afield from the illumination fiber [20, 21].
The fiber separation can be tailored to optimize recovery
of subsurface signal and reduce fluorescence interferences
from the superficial layer. Excitation of a sample using a
defocused laser, and collection of Raman signal through a
sample is the basis for transmission Raman (Fig. 1d)
[22–24]. Transmission Raman also provides representa-
tive sampling and suppresses fluorescence from superfi-
cial layers, rapidly providing a bulk Raman measurement
of a pharmaceutical formulation [25, 26]. Backscattered,
wide area, and SORS can be used in-line, on-line, at-line,
or off-line, whereas transmission Raman is commonly
used as an off-line PAT.
Two other configuration variants deserve mention: Raman
tomography and enhanced reflection Raman. Over a large
anatomic site, such as a leg or wrist, backscattered, diffusely
scattered, and transmitted Raman signal can be simultaneous-
ly measured at multiple locations to generate a 3D image. This
approach, known as Raman tomography, noninvasively pro-
vides dimensional, anatomic location and chemical informa-
tion. Raman tomography was developed in 2008 as an aca-
demic research tool for transcutaneous measurement of bone,
with potential application in pharmaceutical tablet analysis
[27–29]. Enhanced reflection is the addition of a reflecting
mirror, integrating sphere, or photon diode, to backscattered,
SORS, or transmission configurations to improve signal re-
covery and selectivity in sampling thin layers. This approach
is effective because elastically scattered photons can be
reflected back into the sample and possibly undergo inelastic
scattering [30]. Enhanced reflection Raman coupled into a
wide area configuration improves layer selectivity and
Fig. 1 Schematic comparing variants of sample excitation (solid line)
and signal collection [dashed line(s)] used in Raman spectroscopy in
measuring turbid media. (a) Backscattered Raman is a commonly used
geometry that uses a single site of excitation with collection of signal
close (<1 mm) to the excitation. As applied to Raman microscopy, this
approach is called epi-illumination as a single microscope objective is
used to excite the sample and collect Raman signal. The sampling
volume in backscattered Raman is generally small, both in the lateral
and axial dimensions. Thus, backscattered Raman is a good approach
for measuring a surface. (b) Overlapping a defocused or wide laser
beam with multiple collection fibers in a backscattering-like geometry
is called wide area Raman (also known as large volumetric or global
illumination Raman). (c) Separating collection fibers from the sample
excitation by a small distance (Δd = 1–6 mm) enables collection of
diffusely scattered Raman photons, known as a spatially-offset Raman
spectroscopy (SORS). (d) Transmission Raman collects Raman photons
diffusely scattered through a sample. Wide area, spatially-offset Raman
spectroscopy (SORS) and transmission Raman provides representative
sampling in turbid media and enables collection of Raman signal from
buried layers in a layered sample
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provides a bulk measurement similar to transmission Raman
[31, 32] and improves selectivity in thin film measurements in
transmission Raman [33]. The technique is easy to implement
and does not require engineering modifications to equipment.
These features give enhanced reflection Raman an advantage
over transmission Raman, which is difficult to implement as
an on-line PAT, for the purposes of on-line process control by
Raman spectroscopy.
There are two main approaches to analyzing Raman data:
univariate and multivariate. A univariate approach uses
Raman band features of area, intensity, or center of gravity
to understand the sample chemistry. Most univariate Raman
data are reported as band ratios, where band intensities or
areas are ratioed. Band ratios have been correlated to a mate-
rial’s mechanical properties, chemical composition, or a phar-
maceutical solid’s crystal form. Although a univariate data
analysis is straightforward to employ, it requires that the com-
ponents of interest have distinguishing and unique Raman
bands. Important bands overlap in biological tissue, pharma-
ceutical formulations, or bioprocesses, and use of multivariate
data analysis techniques is required. Multivariate data analy-
sis, or chemometrics, is widely used in biomedical Raman
spectroscopy [34], pharmaceutical imaging [35], and process
analytical technology [36]. Partial-least squares (PLS) and
principal components analysis (PCA) are the commonly used
models in pharmaceutical and bioprocessing [37]. Model
transferability, validation, and robustness are important con-
siderations, regardless of model type. Criteria to assess model
suitability may include standard error of calibration (SEC),
standard number of factors used, and coefficient of determi-
nation (R2). However, many variations of model suitability
criteria have been reported, depending on the manufacturing
process.
Considerations in process Raman spectroscopy
Within the process environment, the sampling flexibility of
Raman spectroscopy means that Raman can be employed as
an off-line, at-line, on-line, or in-line (or in situ) PAT. There
are additional logistical considerations when translating
Raman spectroscopy into a process environment. Two reviews
provide a comprehensive list [38, 39]. Data integrity and com-
patibility with control systems or quality risk management
systems require additional software engineering. Process con-
ditions, chemical compatibility of immersion probes, environ-
mental conditions, and operator safety need to be reviewed
thoroughly before implementing any PAT. A process-
specific discussion of these considerations is provided by
Hart et al., for a heterogeneous etherification reaction [40].
The manufacturing process may require additional supplier
qualification, especially if an excipient’s material attribute is
found to be a critical process parameter [41].
Pharmaceutical manufacturing
Recent years have brought a sea of change in pharmaceutical
manufacturing. Regulatory support, combined with recog-
nized scientific and financial benefits, are major factors in
the widespread adoption of QbD and PAT [42–44]. The phil-
osophical shift to QbD has encouraged new risk-based ap-
proaches in real-time release testing, continuous manufactur-
ing, and statistical process control. Real-time, in-process ana-
lytics have an important role in ensuring quality product and
enabling in-process corrections. Focused-beam reflectance,
infrared, near-infrared, and Raman spectroscopies are attrac-
tive as in-process analytics because they rapidly and nonde-
structively provide chemical and physical properties informa-
tion. The sharp Raman spectral features and compatibility
with aqueous environments are attractive features for in-
process measurements. For many years, these features have
been harnessed to understand pharmaceutical small molecule
crystallization and processing.
API reaction analysis
Raman spectroscopy has an important role in understanding
and controlling the manufacture of an active pharmaceutical
ingredient (API). In-process Raman for reaction monitoring
and analysis during unit operations have been reviewed [6,
45]. Since those reviews, there has been interest in extending
the capabilities of Raman in monitoring highly exothermic,
heterogeneous, or continuous flow reactions. An example
shows how Raman, NIR, FBRM, UV/Vis, and particle vision
were integrated into a single intelligent decision support sys-
tem [46]. Another illustrative example shows Raman-based
control of a model exothermic oximation reaction, which suc-
cessfully controlled accumulation of an unstable intermediate
[47]. Hart et al. published a comprehensive paper on the many
considerations in using a PAT for API synthesis [40]. In that
study, a heterogeneous etherification reaction involving
chloropyrazine and phenol in the synthesis of Compound X
was monitored by Raman spectroscopy. Raman predictions
were used to determine the reaction endpoint. The method
and data model were developed at the laboratory scale
(250 mL). During method development, solvent charges, dif-
ferent batches of input materials (to model variable fluores-
cence background), and different baseline correction routines
were tested. The end of reaction was based on %w/w ether.
Two pilot plant scale (1500 L) reactions were reported. In the
first pilot plant batch, Raman predictions were shown to be
equivalent to HPLC. Only Raman was used as the analytical
control in the second pilot plant batch. As shown in Fig. 2,
Raman predictions of %w/w ether showed that the reaction
was completed 600 min before the batch sheet and process
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description stipulations, indicating more efficient mixing at
pilot scales.
In addition to providing scientific results and discussion,
the authors discussed logistical factors that informed on their
decisions in adopting an on-line PAT strategy. Based on our
experience, the myriad considerations described in the paper
are representative of the industry. The authors discussed how
economic, scientific, and risk management factors were inte-
grated into a control strategy using on-line Raman spectros-
copy. The main economic driver was to reduce batch cycle
time, resulting in a cost of goods savings of the API.
Scientifically, on-line Raman addressed concerns that the
off-line HPLC sample was not representative of the heteroge-
neous reaction mixture. From a risk management perspective,
on-line Raman can be used to troubleshoot if the reaction
endpoint was not achieved, and allowed reaction profiles to
be monitored by chemists 200 miles away.
Pharmaceutical excipient chemical and physical properties
are typically a critical process parameter because they affect
manufacturability, bioavailability, and risk of process-induced
API transformations. Raman spectroscopy measures excipient
material attributes nondestructively and rapidly, with hand-
held systems typically used for this application. A comprehen-
sive database of commonly used pharmaceutical excipients
contains both the Raman spectrum and band assignments
[48]. The excipient spectrum can be affected by different
crystal forms, amorphous content, or process variations. In-
house preparation of excipients or biopharmaceutical formu-
lations may require its own risk-based manufacturing ap-
proach [49]. For example, the crystallization and drying steps
in the preparation of sodium carbonate, an excipient in effer-
vescent tablets, were shown to have a high impact on the
tablet’s performance. Sodium carbonate production, by batch
or continuous processing, was monitored by Raman spectros-
copy, laser diffraction, and X-ray powder diffraction as part of
ensuring a quality excipient [41].
Real-time release testing
The PAT and QbD initiatives marked a shift away from end-
process release testing to real-time release testing (RTRT),
defined in ICH Q8(R2) as Bthe ability to evaluate and ensure
the quality of in-process and/or final product-based on process
data^ and typically uses a combination of controlling process
parameters and monitoring product attributes. A RTRT strate-
gy may include at-line chemical and physical property mea-
surements of raw materials, spectroscopic monitoring of con-
centration and uniformity during blending, particle size distri-
bution measurement after granulation, imaging or spectrosco-
py of coating, and a multivariate dissolution model [50].
Within the context of RTRT, Raman spectroscopy has made
Fig. 2 A time course of predicted Raman concentrations of phenol and
ether for a second pilot plant batch, with off-line HPLC and theoretical
limit of ether. In situ Raman spectroscopy was used to control a
heterogeneous etherification reaction, with Raman measurements of ether
%w/w used to predict end of reaction. Reagent was added from 0
to ~180 min followed by a line wash, which accounts for the profile
disturbance at ~ 240 min. In the process description and batch sheet, the
reaction would have been completed at ~ 1250 min and at that time a
sample would be collected for offline HPLC analysis (square in figure).
In situ Raman data showed reaction completion nearly 600 min before
stipulated time. The data suggest that batch cycle time could be reduced
by several hours whenmoving up to the commercial manufacturing scale,
improving process efficiency. Reprinted with permission from Hart,
Richard J., Nicholas I. Pedge, Alan R. Steven, and Kevin Sutcliffe. BIn
Situ Monitoring of a Heterogeneous Etherification Reaction Using
Quantitative Raman Spectroscopy.^ Organic Process Research &
Development 19, no. 1 (January 16, 2015): 196–202. doi:10.1021/
op500027w. Copyright 2016 American Chemical Society
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important contributions as a PAT in pharmaceutical unit oper-
ation of blending, granulation, tableting, and coating. We fo-
cus on new research in in-line or off-line Raman measure-
ments of content uniformity and tablet coating.
Raman PAT tools are robust to particle size and provide
representative sampling. Tablets and capsules are the most
common pharmaceutical formulation, which is reflected in
the number of Raman reports on tablets or capsules. As an
off-line PAT, transmission Raman and micro-scale wide area
Raman rapidly and nondestructively provides API measure-
ments in tablets. Pharmaceutical applications of transmission
Raman consistently report rapid API quantification with suit-
able prediction model error, and significant reduction of fluo-
rescence or tablet coating signal [24, 25]. As a first screen of
content uniformity in pharmaceutical tablets or capsules,
transmission Raman can measure API distribution, poly-
morph impurities, to 0.1 %, and insoluble excipients that can-
not be measured using HPLC. It is possible to obtain even
lower API quantification levels using wide field Raman.
Using a micro-scale wide field Raman mapping instrument,
Li et al. recently demonstrated trace API quantification, with
limits of detection below 0.1 %.With a prediction accuracy of
2.4 %, Raman provided quantification to 0.03 % similar to
0.041% byHPLC [51]. Application of transmission Raman to
quantify API in a bilayer tablet was reported by Zhang and
McGeorge [33]. A modified Kubelka-Munk model of optical
scattering and photon transport showed that the measured API
Raman signal was a function of API concentration, and thick-
ness of API layer and thickness of excipient layer. A Design of
Experiment approach to experimentally verifying model pre-
dictions showed that each layer had different optical scattering
properties so that tablet orientation had an effect on the photon
attenuation coefficient and recovery on sublayer Raman sig-
nal. A transreflectance configuration improved upon layer se-
lectivity and enhanced signal 6-20 fold.
Low levels of polymorph impurities were examined in the
laboratory on a model tablet using NIR, backscattered, and
transmission Raman spectroscopies [52]. Both backscattered
(200 μm spot size) and transmission Raman (8 mm spot size)
were better than near-infrared at identifying low levels (0.6–
0.7 %) of a polymorph impurity in a simulated tablet model.
Transmission Raman measured more volume of the table
more rapidly and with less model prediction error
(RMSEC = 0.29, R2 = 0.998) than backscattered Raman
(RMSEC = 1.11 R2 = 0.965). Backscattered Raman measure-
ments were collected at 16 sites on the tablet and the data were
averaged to avoid sub-sampling but this approach does not
address sub-sampling within the tablet volume since
backscattered Raman measures surfaces with minimal contri-
butions from deeper layers. Essentially, the authors did not
control for differences in the sampling volume between
backscattered Raman and transmission Raman. A study of
pharmaceutical capsules using confocal Raman microscopy
and transmission Raman also directly compares instrument
performance without controlling for differences in sampling
volume [25]. A more direct comparison would be of the two
variants, which employ a defocused laser: wide area and trans-
mission. Photon transport in wide area and transmission
Raman were modeled using Monte Carlo and experimental
validation of the model [22, 31]. Both studies reported that
transmission Raman enabled quantification of small quantities
in deep layers, and backscattered Raman was highly surface-
specific. Incorporation of a reflecting surface into the wide
area setup, such as a reflective belt or station, increased the
ability of wide area Raman to probe in deep layers. Although
transmission and enhanced reflection Raman provided similar
bulk measurements, enhanced reflection can be used as an in-
line PATwhile transmission Raman is an off-line PAT.
Content uniformity is challenging to measure in non-oral
dosing formulations where heterogeneity in API distribution
may affect bioavailability. A recent example highlights how
the spatial resolution and chemical specificity of Raman spec-
troscopy can be used to understand multiple content uniformi-
ty parameters such as API concentration and spatial heteroge-
neity. Wide area Raman spectroscopy of dapivirine in a poly-
meric controlled release device predicted API values, assessed
initial process capability, and demonstrated that heteroge-
neous API distribution in the device would not affect product
specifications [53]. Another example of measuring spatial het-
erogeneity in API distribution was reported by Baronsky-
Probst et al. where off-line Raman imaging was used to mea-
sure API distribution in a hot melt extrusion [54].
Raman has demonstrated value as an in-line PAT for batch
or continuous tablet coating processes, providing both process
control and real-time coating release [55, 56] and capable of
meeting ICH Q2 guidelines for an active coating process [4].
Flow or continuous manufacturing
Intense reaction conditions, non-traditional chemistries, and
miniaturized reactors are hallmarks of continuousmanufactur-
ing. One of the earliest applications of continuous reaction
monitoring was reported in 1997, where on-line Raman spec-
troscopy was used to measure the continuous reaction be-
tween phosphorus and chlorine to produce phosphorus
trichloride [57]. Owing to the Bboiling, toxic, pyrophoric,
and corrosive reaction mixture,^ an on-line reaction analysis
tool was needed. On-line dispersive Raman was selected to
replace on-line FT-Raman. Raman spectroscopy was able to
directly measure all components of interest throughout the
reaction, was sensitive to better than 1 % for reactants and
products, and provided fast feedback. Continuous
manufacturing is commonly used in chemical and petrochem-
ical industries, with pharmaceutical applications only recently
realized. Extension of continuous manufacturing principles to
642 K.A. Esmonde-White et al.
the pharmaceutical industry is now applied from primary API
processing to Bpowder to tablet^ secondary processing [58,
59].
On-line PAT in continuous manufacturing reactors elimi-
nates the need for slow off-line analyses, and improves the
ability to make timely process control decisions. Feasibility
studies show that Raman spectroscopy can be used to monitor
continuous heterogeneous catalysis reactions [60] and catalyt-
ic oxidation reactions [61] in a microfluidic reactor (or
microreactor). Roberto et al. reported on-line Raman monitor-
ing of an esterification of benzoic acid in the NeSSI sampling
system [62]. Incorporation of a PLS model enabled predic-
tions of chemical conversion of benzoic acid to methyl ben-
zoate. Mid-infrared and Raman combined with PLS and mul-
tivariate statistical process control (MSPC) to provide real-
time quality assurance for flow synthesis of an oligonucleotide
[63]. Raman, X-ray powder diffraction, and laser diffraction
were used to monitor continuous or batch production of sodi-
um carbonate, an excipient in effervescent formulations [41].
These examples demonstrate that Raman is an important on-
line PAT in continuous synthesis. In secondary manufacturing,
Fonteyne et al. reported successful prediction of residual
moisture content using on-line Raman and near-infrared and
prediction of granule flowability using photometric imaging
during a continuous granulation production [64].
Bioprocessing
Raman spectroscopy of biological molecules has a rich histo-
ry. The well-known benefits of Raman spectroscopy, includ-
ing sharp spectral features that correlate to a sample’s chemi-
cal or molecular structure properties, nondestructive nature,
and compatibility with aqueous systems, are attractive features
for tissue and cell culture studies. Mineralized biotissues, olig-
omers, polypeptides, and proteins were among the first bio-
logical species examined by Raman spectroscopy [65, 66].
Raman studies into collagen and globular proteins provided
insight into the protein’s secondary structure and
complemented circular dichroism and X-ray diffraction stud-
ies. Raman studies of fatty acids, amino acids, polysaccha-
rides, metabolites, carotenoids, nucleic acids, and glycopro-
teins soon followed. There are excellent reviews providing
Raman spectra of biomolecules, complete with tables of band
assignments [66, 67]. Biological and biomedical Raman ap-
plications emerging in the 1990s had an emphasis on histopa-
thology, disease diagnosis, biological tissue examination, and
in vivo glucose monitoring [68–70]. Concurrent to biomedical
application development, there was an effort to use Raman to
understand metabolism during fermentation or cell culture
bioprocesses.
At the time on-line Raman of bioprocesses was first report-
ed in the late 1980s, there was strong literature in Raman
spectroscopy of amino acids, metabolites, alcohols, and poly-
saccharides. Raman spectroscopy was understood to be a vi-
able choice for in situ bioprocess monitoring but there were a
limited number of published reports, and literature reviews in
2004 and 2010 reflected that understanding [10, 71]. Since
those reviews, new technology has enabled industrial applica-
tions, and, as a result, many papers have emerged since 2010
that demonstrate successful application of Raman spectrosco-
py to monitor and control bioprocesses. In situ, simultaneous
measurement of nutrients, metabolites or by-products, cell
density (or biomass), and method transferability are features
that have made Raman spectroscopy an important PAT in
bioprocessing.
The first bioprocess studied by Raman spectroscopy was
fermentation, and there is ongoing research to further optimize
in situ quantification. Shope et al. reported in 1987 on-line
Raman measurement of fermentation components such as
methanol, ethanol, and acetone [72]. Other reports include
off-line Raman measurements of glucose, glutamine, lactic
acid, and ammonia drawn from a cell culture bioreactor [73],
or in-line Raman measurements of ethanol, glucose, and fruc-
tose of Saccharomyces cerevisiae during alcoholic fermenta-
tion [74]. The first FT-Raman study in 2001 reported off-line
measurement of glucose, ethanol, and cell density of
S. cerevisiae during ethanol fermentation, with the goal of
process control [75]. Another early in-line Raman study re-
ported direct measurement of carotenoid production by
Phaffia rhodozyma, and the Raman data were used to deter-
mine an optimal feeding strategy [76]. In these early studies,
academic researchers used laboratory equipment or custom-
built fiber optic probes to perform their measurements.
Recent research in Raman spectroscopy of fermentation
bioprocesses have developed novel fiber optic probes and
refined data analysis models, with the goal of in situ quantifi-
cation of important parameters such as glucose, ethanol, and
cell concentration. In situ Raman quantification of glucose,
ethanol, and yeast concentrations during a S. cerevisiae fer-
mentation was reported by Picard et al. in 2007 and Iversen
et al. in 2014 [77, 78]. In the study by Iversen et al., a
specially-designed probe delivered 785 nm light and collected
Raman signal. The probe was directly inserted into the 1 L
bioreactor, enabling in situ Ramanmeasurements. Raman pre-
dictions were compared with HPLC or UV/Vis reference mea-
surements. The authors performed reference measurements of
pure component ethanol/glucose mixtures (1:1 v/v 70 g/L
ethanol:20 g/L glucose) while varying yeast cell concentra-
tions in order to understand the effect of optical density on
Raman signal attenuation. Raman spectra of pure components
and model results are shown in Fig. 3. From the optical scat-
tering experiments, the authors found a non-uniform baseline
shift. The oscillating pattern in the Raman spectra was consis-
tent with yeast cell concentration. Proposed sources of the
oscillation pattern were changes in angular scattering
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intensity, partial Mie scattering, or resonance fluorescence.
Further inspection on the effect of increasing optical density
showed significant variance in the response of analyte’s
Raman signal, but little effect on fluorescence. For example,
the ethanol band at 877 cm–1 was attenuated more quickly
than the glucose band at 1123 cm–1 or the water band at
1627 cm–1 with yeast cell concentration. Because a general
extinction relationship could not be calculated, a relation-
ship was developed for each component: glucose, ethanol,
and cell biomass. Correction of Raman signal attenuation re-
sulted inmarked improvement to the root mean square error of
prediction over non-corrected data for glucose and ethanol. In
this study, modeling the optical scattering resulted in im-
proved quantification.
Production of protein therapeutics by mammalian cells is
the most widely used bioprocess because of its ability to prop-
erly produce and fold a recombinant protein, with 60–70 % of
biopharmaceuticals using this bioprocess [79, 80]. Since
1986, an increased understanding of cell biology, gene trans-
fer mechanisms, media composition, and process control has
resulted in significant improvements to cell viability and titer
[80]. Most cell culture bioprocesses use CHO cells, fed by
glucose. Glucose is a critical process parameter, as it affects
the cell’s metabolic profile, production of waste products, and
post-translational non-enzymatic glycosylation of proteins
[81]. CHO cells are typically fed in a batch, known as fed-
batch, where glucose is delivered into the bioreactor as a large
bolus at set time points, and the time points are based on a
priori process knowledge and off-line analysis. However, this
approach is not ideal for several reasons. It is labor- and
resource-intensive, increases the risk for contamination, and
does not adequately control glucose and lactate in a cell cul-
ture bioreactor. Noninvasive, real-time PAT measurements
combined with PID or closed-loop feedback control can opti-
mize feeding strategies, improving yield and titer.
Raman spectroscopy has an important role in cell cul-
ture bioprocesses, providing in situ measurements and en-
abling real-time process control. In situ Raman measure-
ments were first reported in 2011 by Abu-Absi et al. [82].
Raman spectra were collected every 2 h over the course of
~14 d in a 500 L bioreactor growing CHO cells. The
Raman spectrum enabled simultaneous measurement of
glucose, glutamate, glutamine, lactate, ammonia, total cell
density (TCD), and viable cell density (VCD). Raman
data models based on PLS regression accurately predicted
changes in nutrient and byproduct levels, and correlated
with reference or calculated values. Raman estimates of
TCD and VCD correlated with reference data, with slight
deviations observed at very low cell densities at d 0–2.
Later studies extend the capability of the technique by
demonstrating cross-scale model transferability within de-
velopment scale from 3 to 15 L [83], and from develop-
ment scale (3, 200 L) to clinical manufacturing scale
(2000 L) [84]. In these models, it was assumed that the
bioprocess could be modeled using a linear model.
Two Raman-based feedback control studies underscore
the capability of Raman to not only provide in situ chem-
ical information, but also control protein quality. In a fea-
sibility study by Craven et al., Raman spectroscopy was
integrated with a nonlinear model predictive controller
(NMPC) [85]. Raman spectra were collected every
6 min in a 15 L bioreactor growing CHO cells. A PLS
data model was used to predict glucose, glutamine, lac-
tate, and ammonia. PLS-predicted glucose concentrations
were input into a NMPC, which communicated with an
OPC-controlled pump to adjust the feed rate. Raman data
correlated with off-line reference measurements. This ap-
proach allowed the bioreactor to maintain glucose concen-
tration of 11 mM throughout the bioprocess. Off-line sim-
ulation studies were first used to optimize the controller
configurations, then applied to two PAT scenarios. The
first PAT scenario mimicked a case where off-line mea-
surements are collected, and the feed rate is adjusted once
per day. The second PAT scenario mimicked a case where
in situ measurements are collected throughout the day and
enabled closed-loop feedback control. Overall, the NMPC
demonstrated good performance despite slight process–
model mismatches, high measurement noise, unexpected
occurrences, and long measurement intervals. In another
study, Berry et al. demonstrated that a simplified Raman
model for glucose feedback control in a fed-batch CHO
bioprocess using two short cell-free and eight bench-scale
production bioreactors successfully reduced non-
Fig. 3 (a) Raman spectra after fluorescence corrections of reference
components: ethanol, glucose, water, glycerol, and lactic acid, and (b)
standard plot of baseline-corrected spectra for a simulated fermentation of
100 g/L glucose up to 50 g/L. Ethanol measured at 877 cm−1 (diamond),
y = 21.406x + 12.553, R2 = 0.9959; 1046 cm−1 (multiplication sign),
y = 3.0716x + 138.07, R2 = 0.9569 at 1455 cm − 1 (triangle),
y = 6.4871x + 138.52, R2 = 0.984. Glucose measured at 514 cm−1
(circle), y = 2.8793x + 11.362, R2 = 0.9973, and 1,123 cm−1 (square),
y = 4.2116x + 24.177, R2 = 0.994. Reprinted with permission from
Iversen, Jens A., Rolf W. Berg, and Birgitte K. Ahring. BQuantitative
Monitoring of Yeast Fermentation Using Raman Spectroscopy.^
Analytical and Bioanalytical Chemistry 406, no. 20 (2014): 4911–4019.
doi:10.1007/s00216-014-7897-2. Copyright 2014 Springer.
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enzymatic glycosylation of the target protein from 9 to
4 % [81].
Off-line Raman spectroscopy of CHO fed-batch bioprocess
fresh and spent media enabled glycoprotein yield prediction
[86]. The batch scale varied from 1 to 5000 L, representative
of laboratory and manufacturing scales. Raman spectra were
analyzed by PLS using the fingerprint region (400–1853 cm–
1), which resulted in high relative error of prediction (REP,
7.9–13.1 %) and poor correlations (R2 < 0.4). Then,
Competitive adaptive reweighted sampling (CoAdReS) and
ant colony optimization (ACO) variable selection techniques
were used to select a limited number of variables, or spectral
regions, to improve model accuracy. The use of CoAdReS and
ACO resulted in a more accurate PLS model, as evidenced by
a reduction in REP to 2–4 % and an R2 > 0.9 for CoAdReS
and R2 > 0.85 for ACO.
Chemometric modeling of bioprocesses
Spectroscopic sensors are sometimes called Bsoft sensors^ in
the bioprocessing literature because spectroscopic data is
modeled in software programs and the models provide infor-
mation akin to hardware sensors [87, 88]. The use of data
analysis models is important in order to extract the maximum
amount of information from Raman spectra, and there is con-
siderable research in this area. A 2012 review by Lourenço
et al. provides an overview of univariate and multivariate
models used in bioprocessing, which include PLS and PCA
[37]. Fermentation or cell culture bioprocesses involve com-
plex data with limited first principles knowledge on the pro-
cess. How does a data model derive meaningful information
from such a dataset? There are two reported approaches: ex-
plicit and implicit models.
Explicit models are sometimes called Bfirst principles,^
parametric or hard models. A commonly known explicit mod-
el is the Beer-Lambert law, which describes the relationship
between a material’s optical absorbance and concentration
[89]. Explicit models describe the system in terms of mea-
sured independent variables that produce dependent variables
and essentially force the data to obey a mathematical model.
Use of the Bexplicit model^ term has only been found in two
Raman/bioprocessing papers, and the definition of an explicit
model in this context means that an internal reference was
used to account for physical variations such as laser attenua-
tion or optical scattering [90, 91]. Even if the Bexplicit model^
term was not necessarily used, other studies have reported
using an internal standard to improve quantification. An ex-
plicit model was used in the earliest examples of Raman anal-
ysis of bioprocesses, using the weak water peak ~1640 cm–1
as an internal standard [72, 73]. This approach has been re-
cently extended to in situ Raman monitoring of E. coli culture
[90], confocal Raman microscopy of media [91], and yeast
fermentation [78]. A 2007 report of yeast fermentation used
the 980 cm–1 sulfate band as an internal standard [77]. Even
when an explicit model is used, there are often limitations to
the knownmodel, which may affect its robustness. In the 2014
study by Iversen et al., the authors noted that the relationship
of yeast cell concentration with light extinction could not be
adequately described using Beer-Lambert law, that non-linear,
wavelength-dependent attenuation necessitated describing the
relationship for each individual component using quadratic
equations, and that the modeling was valid because the yeast
cells were the only Lorenz-Mie scattering particles in the
bioprocess [78]. An explicit model for CHO cell culture fed-
batch was developed to account for bioprocess nonlinearities,
with demonstrated success for in-process control of glucose
concentrations [85]. Correcting for turbidity in aqueous media
is of interest for Raman spectroscopy of water quality appli-
cations, and the developed approaches may be adapted for
bioprocessing [92].
Implicit models are also known as non-parametric or soft
models. Implicit models are based on correlation or covari-
ance, assume no knowledge about the physical laws of the
system, nor assume variable independence, and do not force
the data to fit a known model. Measured training sets span a
representative range of analyte concentrations. Implicit
models account for physical or process variations without
necessarily modeling that variation, and most reported models
are implicit in that they do not assume a physical description
of the system. Implicit models are especially useful when
there is spectral overlap of components, as is the case in cell
culture bioprocesses.
Model robustness and transferability are important consid-
erations. Generic models are developed in one process, com-
prising a set of cell lines, media, and process conditions, and
are sufficiently robust so that they can be applied to other
processes or other Raman instruments. In this aspect, explicit
models have an advantage since they are generally more ro-
bust than implicit models. Transferability of implicit models
relies on the training set, and may not be applicable to other
systems. However, if the training set of an implicit model
adequately captures process variability as a result of different
cell lines, media composition, or bioreactor volume, it may be
considered a Bgeneric^model; implicit models have been suc-
cessfully transferred, as demonstrated since 1999. Shaw et al.
demonstrated that a multivariate model resulted in the least
amount of prediction error, and was the first to show that a
model developed for one process could be successfully trans-
ferred as long as the same process was used [93]. Cross-scale
transferability of implicit models, for the same bioprocess,
was demonstrated within the development scale and from de-
velopment to manufacturing [83, 84]. A recent study by
Mehdizadeh et al. successfully demonstrated the use of a ge-
neric PCA/PLS model for bioreactors involving CHO cell
lines [94]. Model predictions of glucose, lactate, and viable
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cell density were shown to be adequate for independent vali-
dations at the large pilot scale and in a cell line that was not
included in model development. To our best knowledge, there
are no reports of cross-scale transferability of explicit models
in bioprocessing.
There are examples of explicit and implicit models in the
bioprocessing literature, and both model types are suitable for
in situ bioprocess monitoring and control. Although the early
studies of Raman in bioprocesses used an explicit model, the
modern trend is toward an implicit model. There are practical
and scientific factors that contribute to this observed trend. As
soft models became more sophisticated, they became more
useful in their predictive capability, which facilitated their
adoption in modeling bioprocesses. The complexity of the
system, combined with logistical and time constraints, may
preclude development of an explicit model despite the strong
benefit of an explicit model to explicitly account for biochem-
ical and process variations. Hybrid models, also called grey
models, combine hard constraints with soft model flexibility
and several have been proposed for bioprocesses [85, 95–97].
We anticipate more basic research and applications incorpo-
rating novel chemometric models into bioprocessing, enabling
even more sophisticated analyses.
Conclusions
Emerging technologies, a dynamic regulatory landscape, and
new scientific challenges continue to expand the applicability
and utility of Raman spectroscopy as a PAT in pharmaceutical
manufacturing, and bioprocessing. Technological develop-
ments in transmission Raman enable nondestructive and rapid
bulk tablet or capsule analysis. Transmission Raman is used
primarily for off-line measurements of content uniformity. In-
line Raman spectroscopy for API reaction monitoring or sec-
ondary pharmaceutical processes has been shown to enable
real-time process corrections. Extension of Raman to contin-
uous manufacturing environments has been demonstrated
since the 1990s, and we expect to see more applications in
this environment. Although not discussed in this review, there
is much research in developing enhancement techniques for
Raman spectroscopy. Surface-enhanced Raman spectroscopy
(SERS) can be a powerful tool for in-process measurements,
and feasibility has been shown for SERS of bacterial analysis
and in bioprocessing [98–102]. Raman is a valuable PAT for
fermentation or cell culture bioprocess monitoring and con-
trol. Simultaneous, in situ measurement of nutrients, metabo-
lites, and cell concentration is an attractive feature of Raman.
Based on our experience and a recent conference presentation,
Raman is used in bioprocess monitoring and control from the
laboratory scale to GMP production. We anticipate new re-
ports describing the integration of Raman into a GMP
environment.
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